Key result
The bivalent RSV prefusion F vaccine administered during pregnancy demonstrated an 81.8% efficacy in preventing severe lower respiratory tract illness in infants within 90 days of delivery.
Why the study?
An effective RSV vaccine for women during pregnancy and for infant protection had eluded scientists and clinicians for 50 years.
Does the bivalent RSV prefusion F vaccine administered during pregnancy prevent severe lower respiratory tract infection in infants?
Does the bivalent RSV prefusion F vaccine administered during pregnancy prevent severe lower respiratory tract infection in infants?
The FDA-approved bivalent RSV prefusion F vaccine administered during pregnancy at 32 to 36 weeks' gestation is approximately 82% effective in preventing severe lower respiratory tract infection in infants.
Answers are grounded in this paper and cite their sources.
Supports maternal RSV vaccination in pregnancy; leaves open durability, real-world effectiveness, and safety monitoring.
FDA approved in August of this year, the new bivalent RSV prefusion F vaccine represents a major and welcomed breakthrough, as an effective vaccine for women during pregnancy and for infant protection has eluded scientists and clinicians for 50 years
No takes yet. Share an insight, caveat, or question.
Patrick Duff (2023) conducted a review in Respiratory syncytial virus (RSV) infection. Bivalent RSV prefusion F protein-based (RSVpreF) vaccine vs. Placebo was evaluated on Medically-attended severe RSV-lower respiratory tract infection in infants within 90 days after birth (Vaccine efficacy 81.8%, 95% CI 40.6-96.3). The bivalent RSV prefusion F vaccine administered during pregnancy demonstrated an 81.8% efficacy in preventing severe lower respiratory tract illness in infants within 90 days of delivery.
Synapse has enriched 10 related papers. Consider them for comparative context: